Regenxbio (RGNX) Current Deferred Revenue (2014 - 2026)
Regenxbio (RGNX) recorded Current Deferred Revenue of $9.88 million in Q2 2026, down 29.3% from $13.98 million a year earlier but up 67.0% from the prior quarter.
Powered by 
Analysis
Regenxbio (RGNX) Current Deferred Revenue (2014 - 2026) Analysis & Trends
At the end of FY2025, Regenxbio reported Current Deferred Revenue of $10.45 million.
- Annual Current Deferred Revenue has a five-year compound annual growth rate of 87.7% (FY2020 to FY2025).
- Across earlier years, Current Deferred Revenue came in at $115,000 in FY2024 (-22.3%), $148,000 in FY2023 (-91.9%), $1.83 million in FY2022 (-45.1%) and $3.33 million in FY2021 (+642.3%).
- Quarterly Current Deferred Revenue has ranged from $13,000 in Q1 2024 to $13.98 million in Q2 2025 over the past five years.
- Peak year-over-year performance for Current Deferred Revenue in the last five years was growth of 743.8% in Q1 2022, against a decline of 99.0% in Q1 2024 at the low end.
- Per Business Quant, the preceding three quarters came in at $5.92 million (Q1 2026), $10.45 million (Q4 2025) and $13.2 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn |
| 10 | Regenxbio | 418.33 Mn | -341.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.88 Mn |
| Dec 31, 2025 | 10.45 Mn |
| Sep 30, 2025 | 13.20 Mn |
| Jun 30, 2025 | 13.98 Mn |
| Mar 31, 2025 | 13.59 Mn |
| Dec 31, 2024 | 115,000.00 |
| Sep 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | 442,000.00 |
| Jun 30, 2023 | 448,000.00 |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 6.64 Mn |
| Mar 31, 2022 | 3.33 Mn |
| Dec 31, 2021 | 3.33 Mn |
| Sep 30, 2021 | 395,000.00 |
| Jun 30, 2021 | 395,000.00 |
API Access
Regenxbio Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RGNX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "RGNX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RGNX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();